RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Phase 2 Completed 33 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Massachusetts General Hospital · collab Novartis · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer conditions and the results have been promising.

Timeline

Start: 2007-01
Primary completion: 2009-01
Completion: 2009-05

Outcome

Missed primary endpoint

paper only seven patients (21%) had stable disease at the first restaging scans performed at 2 months. PMID 19047305 ↗

Publications

Results Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10;27(2):193-8. doi: 10.1200/JCO.2008.18.9514. Epub 2008 Dec 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	10 mg	—